Newland Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Cash & Equivalents	169	281.58	270.02	51.13	34.21
Trading Asset Securities	549.55	525.16	589.5	701.36	8.67
Cash & Short-Term Investments	718.55	806.75	859.52	752.49	42.88
Cash Growth	-10.93%	-6.14%	14.22%	1654.94%	17.63%
Accounts Receivable	270.55	332.61	240.9	360.46	269.6
Other Receivables	0.09	0.24	0.19	0.26	0.16
Receivables	270.65	332.85	241.09	360.72	269.76
Inventory	72.37	45.06	31	53.52	78.57
Other Current Assets	5.11	10.37	25.04	20.38	9.8
Total Current Assets	1,067	1,195	1,157	1,187	401
Property, Plant & Equipment	659.65	574.78	388.2	295.52	225.67
Other Intangible Assets	49.99	36.82	38.08	38.77	39.71
Long-Term Deferred Tax Assets	-	-	-	-	1.01
Long-Term Deferred Charges	1.34	3.38	5.61	1.29	-
Other Long-Term Assets	1.85	3.73	20.96	11.08	0.51
Total Assets	1,780	1,814	1,610	1,534	667.9
Accounts Payable	97.68	138.66	87.75	106.37	80.26
Accrued Expenses	18.19	23.78	30.33	18.18	27.81
Short-Term Debt	-	0.73	-	-	91.33
Current Portion of Long-Term Debt	2.81	-	-	-	4.66
Current Portion of Leases	-	-	1.99	2.84	-
Current Income Taxes Payable	2.33	-	-	-	3.05
Current Unearned Revenue	3.28	5.32	4.43	4.61	1.68
Other Current Liabilities	46.07	48.3	14.96	24.01	11.8
Total Current Liabilities	170.35	216.78	139.47	156.01	220.58
Long-Term Debt	-	-	-	-	30.39
Long-Term Leases	2.89	2.25	0.73	2.88	-
Long-Term Unearned Revenue	44.23	41.88	10.04	10.3	10.56
Long-Term Deferred Tax Liabilities	11.02	9.77	9.78	5.39	-
Total Liabilities	228.49	270.69	160.02	174.58	261.53
Common Stock	392.08	280.06	200.04	133.36	100
Additional Paid-In Capital	532.74	644.77	724.78	791.46	5.49
Retained Earnings	619.93	610.7	517.09	424.79	292.48
Comprehensive Income & Other	6.59	6.67	6.11	6.33	4.56
Total Common Equity	1,551	1,542	1,448	1,356	402.53
Minority Interest	-0.33	0.85	1.47	3.25	3.85
Shareholders' Equity	1,551	1,543	1,449	1,359	406.38
Total Liabilities & Equity	1,780	1,814	1,610	1,534	667.9
Total Debt	5.69	2.98	2.72	5.72	126.38
Net Cash (Debt)	712.86	803.77	856.8	746.77	-83.5
Net Cash Growth	-11.31%	-6.19%	14.73%	-	-
Net Cash Per Share	1.82	2.05	2.19	2.48	-0.28
Filing Date Shares Outstanding	388.28	392.08	392.08	392.08	294
Total Common Shares Outstanding	388.28	392.08	392.08	392.08	294
Working Capital	896.33	978.24	1,017	1,031	180.43
Book Value Per Share	4.00	3.93	3.69	3.46	1.37
Tangible Book Value	1,501	1,505	1,410	1,317	362.82
Tangible Book Value Per Share	3.87	3.84	3.60	3.36	1.23
Buildings	-	211.94	169.21	151.69	148.36
Machinery	-	295.69	235.66	187.31	125.82
Construction In Progress	-	222.1	106.7	55.35	33.02

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.